Why Modern Medicine Must Target the Drivers of Aging | Karl Pfleger, Aging Biotech Investor

Is modern medicine fighting the wrong battle? In this episode of The Health Curve, host Dr. Jason Arora speaks with Karl Pfleger - former Google engineer turned geroscience investor and advocate - about why focusing on individual chronic diseases is failing us, and why targeting the fundamental biological drivers of aging is the ultimate leverage point for human health.Karl breaks down the Geroscience Hypothesis, why "preventable" chronic diseases like cardiovascular disease and dementia are actually inevitable without intervention, and how upcoming therapeutics could eliminate age-related pathology altogether.⏱️ Chapter Markers00:00 - Welcome 00:20 - From Google to Aging Biology 02:50 - Why Chronic Disease Is Not Preventable 06:15 - The Geroscience Hypothesis Explained 10:15 - Why Karl Rejects the Word "Longevity" 13:06 - Slowing Aging vs. Rejuvenation 17:31 - When to Start Intervening 18:42 - The End Goal of Success 19:35 - What We Can Do Today 24:10 - Therapies Close to Real Use 28:18 - Where GLP-1 Drugs Fit 35:58 - Funding & Regulation Bottlenecks 45:04 - What the Future Looks Like 51:47 - Equity & Global Impact 56:41 - Final TakeawaysKarl's website: agingbiotech.info